Overview
Poland does not treat peptides as a distinct legal category: each compound is assessed under the Pharmaceutical Law of 6 September 2001. Peptides that are authorised medicines (e.g. semaglutide-class drugs, somatropin) are prescription-only and can only be dispensed through licensed pharmacies, while unapproved 'research' peptides such as BPC-157 and TB-500 have no medicinal-product status at all and may not lawfully be sold or supplied for human use. In 2025 the Chief Sanitary Inspector (GIS) and the Chief Pharmaceutical Inspector (GIF) issued a joint public warning stating that offering synthetic peptides online under 'chemical reagent' or 'research material' labelling, while signalling human use, breaks Polish law and can carry criminal liability. Personal importation is also constrained: travellers may carry only a small quantity of medicinal products for their own therapeutic needs, and mail-order supply of prescription medicines is not permitted.
Key Points
- The Chief Sanitary Inspector and Chief Pharmaceutical Inspector have jointly warned against buying and using synthetic peptides sold online as 'chemical reagents for analytical testing', 'reference materials for laboratory research only' or 'products for scientific and development work', stating that offering them for sale in this manner is contrary to Polish law and risks criminal liability. [1]
- Regulators state that products labelled as 'research products' or chemical reagents do not have the status of a medicinal product and have not undergone clinical trials confirming their safety and efficacy, so they may not be sold for medical purposes. [1]
- The regulators identify the legal basis for their position as the Pharmaceutical Law of 6 September 2001 (Dz.U. 2025 poz. 750, as amended) and the Act of 21 April 2017 on combating doping in sport (Dz.U. 2022 poz. 1258), rather than narcotics legislation. [2]
- Authorities note that many of these substances are synthetic hormones, growth factors or metabolism-affecting compounds that appear on the prohibited list in sport, exposing athletes to disqualification and legal liability. [2]
- Poland's national anti-doping agency (POLADA) records that BPC-157 was added by name to group S0 of the WADA Prohibited List in 2022 and that the substance is not approved for human use by any global regulatory body. [3]
- For customs purposes, people arriving in Poland may bring in medicinal products for their own needs without the consent of the President of URPL only in a quantity not exceeding five smallest packages, under Article 68(5) of the Pharmaceutical Law. [4]
- The Ministry of Health has adopted the interpretation, shared by the Chief Pharmaceutical Inspector and the Minister of Finance, that this personal-import allowance covers only products carried by the patient across the border for their own therapeutic needs, an approach used to curb postal shipments of medicines into Poland. [5]
- Article 68(3) of the Pharmaceutical Law permits pharmacies and pharmacy points to conduct mail-order sale only of medicinal products dispensed without a prescription, so prescription-only peptide medicines cannot lawfully be supplied by internet or mail order. [6]
- No Poland-specific statute or scheduling instrument that lists BPC-157, TB-500 or similar research peptides as controlled narcotic or psychotropic substances was located; the point that they fall under pharmaceutical rather than narcotics law reflects the legal bases cited by GIS/GIF and is an inference, not a direct source. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)